OMass Therapeutics Limited

Based in the UK, OMass Therapeutics Limited is a biotechnology company focused on developing innovative small molecule therapeutics for orphan diseases and immunological conditions, utilizing advanced biochemistry techniques. OMass Therapeutics Limited specializes in the development of small molecule therapeutics. Founded in 2016, the company is headquartered in Oxford, UK. It was co-founded by Idlir Liko and Jonathan Hopper, with Ros Deegan serving as the CEO.

In October 2026, OMass Therapeutics Limited raised USD 310 million in series C funding co-led by Novo Holdings, Forbion, and Bain Capital, with participation from Jefferson Life Sciences, SV Health Investors, Janus Henderson Investors, University of Oxford, British Business Bank, Sanofi Ventures, and Syncona. OMass Therapeutics specializes in developing small molecule therapeutics aimed at treating orphan diseases and immunological conditions. Their product portfolio focuses on validated target ecosystems, such as membrane proteins and intracellular complexes, employing advanced biochemistry, native mass spectrometry, and custom chemistry techniques. Their therapeutics primarily serve patients with immunological disorders and rare diseases that are not adequately treated by existing solutions.

OMass operates in Europe, North America, and Asia, targeting healthcare providers, pharmaceutical companies, and research institutions for its innovative therapeutic solutions. In 2023, OMass Therapeutics reported no revenue, with an EBITDA loss of GBP 28,579,921. The company generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions, often involving licensing and collaborative agreements for developing new therapeutics. Revenue streams include milestone payments and royalties from eventual product sales.

The company will use the October 2026 funding to advance OMS1620 through clinical development into phase 2 studies, progress its SLC15A4 inhibitor program, build its development capabilities, expand its multi-geography operations, and attract talent in both the UK and the US.